Rare neuromuscular diseases often lack treatments because developing targeted drugs is slow, costly and risky for companies. A new approach using AI and stem cell models could finally shift the balance.
By Tom Cassauwers
Belgian AI company Kantify was doing business as usual until a cancer diagnosis forced the team to rethink their direction. “We built algorithms for sectors like marketing or transport,” said Ségolène Martin, Kantify’s co-founder and CEO.
